<DOC>
	<DOCNO>NCT02920476</DOCNO>
	<brief_summary>This non-randomized , open label , sequentially enrol phase II study Simon two-step enrollment design evaluate activity TAS-102 previously treat unresectable metastatic squamous non-small cell cancer progression intolerance prior systemic therapy . The trial therapy TAS-102 administer orally 35 mg/m2 dose twice daily . The primary objective trial determine progression-free survival , month , subject receive TAS 102 treatment unresectable metastatic recurrent squamous non-small cell lung cancer .</brief_summary>
	<brief_title>TAS-102 Previously Treated Unresectable Metastatic Squamous Cell Lung Carcinoma ( UF-STO-LUNG-003 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Those eligible patient unresectable and/or metastatic squamous cell nonsmall cell lung cancer disease previously treat Food &amp; Drug Administration ( FDA ) National Comprehensive Cancer Network ( NCCN ) approve platinum doublet immune checkpoint inhibitor . Patients receive therapy must medical reason receive therapy , prior history autoimmune disease . Those molecularly targetable genetic mutation tumor must also receive appropriate specific therapy mutation . All appropriate candidate chemotherapy treatment . Subjects must meet additional follow criterion eligible study participation : Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 2 Life expectancy &gt; 12 week Male female ' age &gt; 18 year Patients childbearing potential must use effective mean contraception . Histologic diagnosis squamous nonsmall cell lung cancer treat adequately metastatic unresectable set platinum doublet chemotherapy regimen immune checkpoint inhibitor , evidence disease progression . Patients receive immune checkpoint inhibitor must medical reason receive therapy , prior history autoimmune disease . Patients receive platinumbased doublet therapy neoadjuvant adjuvant set eligible experienced disease progression within 3 month last dose cytotoxic chemotherapy . Patients neoplasm currently exist FDAapproved target therapy ( epidermal growth factor receptor [ EGFR ] activate mutation , ALK ROS1 gene rearrangement ) must receive targeted therapy either exhibit progressive disease treatment , show intolerant therapy , prior enrollment study . Baseline laboratory value ( bone marrow , renal , hepatic ) : Adequate bone marrow function : Absolute neutrophil count &gt; 1000/µL Platelet count &gt; 100'000/µL Renal function : Serum creatinine &lt; 2.0 mg/dL Hepatic function : Bilirubin &lt; 1.5x upper limit normal ( ULN ) Serum calcium &lt; 12 mg/dL Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study least 6 month last dose study drug minimize risk pregnancy . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . WOCBP include woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Amenorrhea last ≥ 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum folliclestimulating hormone ( FSH ) level great 35 mIU/mL . Males female partner childbearing potential must agree use physicianapproved contraceptive method ( e.g. , abstinence , condom , vasectomy ) throughout study avoid conceive child 6 month follow last dose study drug . Subjects must provide write informed consent willing comply studyrelated procedure . Pregnant lactating female Patients mixed histology NSCLC , adenosquamous carcinoma , squamous component &lt; 50 % assessed lesion Patients mixed histology small cell element Patients receive progressed , intolerant , commonly utilized platinumdoublet therapy ( cisplatin carboplatin pair docetaxel , paclitaxel , nabpaclitaxel , gemcitabine , vinorelbine , etoposide irinotecan ) administer treatment unresectable metastatic lung cancer . Patients receive progressed immune checkpoint inhibitor unless medically ineligible , due prior history pneumonitis , nephritis autoimmune disease . Such patient receive checkpoint inhibitor therapy must assess tumor response earlier 12 week therapy order rule pseudoprogression . Patients receive appropriate prior target therapy lung cancer eligible Any invasive malignancy treat within 3 year prior Cycle 1 , Day 1 Myocardial infarction ischemia within 6 month Cycle 1 ' Day 1 Uncontrolled ' clinically significant dysrhythmia , prolong QT segment Uncontrolled malignant disease central nervous system ( previously treat disease eligible , provide radiographically stable least four week ) Radiotherapy within 2 week Cycle 1 , Day 1 . If radiation administer target lesion must evidence growth radiographic assessment physical examination Major surgery within 2 week Cycle 1 , Day 1 Any co morbid condition ' view attend physician ' render patient high risk treatment complication Subjects must use acceptable method avoid pregnancy entire study period least 6 month last dose study drug . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use protocol therapy might affect interpretation result study put subject high risk treatment complication , opinion treat physician . Prisoners subject involuntarily incarcerate . Subjects compulsorily detain treatment either psychiatric physical illness . Subjects demonstrate inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>lung</keyword>
	<keyword>metastatic</keyword>
	<keyword>carcinoma</keyword>
</DOC>